Aim: The aim of this study was to evaluate acetylcholinesterase (AChE) and pseudocholinesterase (PChE) in whole saliva in patients with Alzheimer's disease (AD) and in healthy subjects. Saliva has a high potential for keeping track of general health and diseases. AD is a type of dementia with reduction in brain cholinergic markers that causes memory, thinking, and behavior problems. Up to 90% decrease in AChE activity has been observed in AD.
INTRODUCTION
Saliva, a fluid from the salivary glands, 1 plays several important roles in the oral health environment. [2] [3] [4] Saliva sampling is a practical, convenient, and reliable means for evaluation of physiological condition, as well as for being used as a good indicator of plasma levels of medicines and hormones, for diagnosis of oral signs of systemic disease, and for evaluating disease severity. Saliva is considered a "mirror of the body's health." Today, saliva is widely used as an acceptable © 2018 Special Care Dentistry Association and Wiley Periodicals, Inc.
diagnostic tool and has helped in better disease detection and monitoring. 5, 6 Saliva as a noninvasive method can be used to monitor plasma levels of biomarkers. 7 Alzheimer's disease (AD) is a chronic neurodegenerative disease characterized by cognitive difficulties and memory and executive dysfunction. 8 In neurodegenerative disorders, neuronal systems are progressively affected. 9 Decline in cholinergic function is closely correlated with cognitive, memory, and learning impairment in patients with AD. 10 AD is diagnosed after excluding other pathological causes on clinical grounds, so a biochemical marker and screening test that aid in clinical detection and differentiation of AD from other cognitive disorders are of great value. 10 Preclinical evaluation can be started before the emergence of clinically overt disease. 9 Decline in cholinergic function is closely correlated with cognitive, memory, and learning impairment in patients with AD. 10 Cholinergic neurons innervate salivary glands, which produce an enzyme called acetylcholinesterase (AChE). Saliva can be used to monitor the same hormones and enzyme levels that are reflected in cerebrospinal fluid (CSF). 10 AChE is expressed in the central nervous system, peripheral nervous system, muscles, blood cells, and saliva. 11 The AChE found in saliva is isolated from salivary gland cells; however, microorganisms may secrete salivary pseudocholinesterase (PChE) in the oral cavity. 12 Salivary AChE is synthesized because of the activity of cholinergic neurons and can be used as a potential enzymatic marker for cholinergic activity. 13 In AD, up to 90% decrease in AChE activity has been observed and the main finding in AD is low brain cholinergic activity. Moreover, AChE shows cholinergic activity. 13 Sayer et al 4 concluded that "salivary enzyme activity may therefore prove to be a useful marker of central cholinergic activity." So, increase or decrease in cholinergic enzyme activities would be expected in AD. Yilmaz 14 concluded that saliva had potential as an easy and convenient sample for early diagnosis of AD using metabolomics. Mushtaq et al 15 showed a low level of AChE in AD and suggested that this enzyme plays an important role in AD pathogenesis. In the study by Sayer et al, 4 salivary AChE activity was reduced in patients with AD, in comparison to that in a control group. In another study on salivary AChE in patients with AD, no significant difference was observed between the case and control groups. 10 In another study, salivary cortisol was higher in patients with AD, which was related to disease severity. 16 Smith et al 17 showed almost 100% elevation of plasma PChE activity in patients with AD. No study has evaluated salivary PChE as a cholinesterase enzyme in AD until now.
Many studies about salivary biomarkers in patients with AD have been conducted [18] [19] [20] [21] [22] [23] ; but to the best of our knowledge, few studies have been performed on salivary cholinesterase enzyme changes and the benefits of saliva in AD. Therefore, the aim of this study is to compare salivary AChE and PChE in patients with AD and in healthy control groups.
METHODS
This study was a case-control study. The Ethics Committee of Hamadan University of Medical Sciences approved the study protocol. Written informed consent was obtained from participants. Thirty patients with AD and 30 healthy controls over 50 years old who were randomly selected from patients and were referred to the clinics in Hamadan University of Medical Sciences from 2011 to 2012 participated in this study. A neurologist confirmed the disease in all subjects. None of the included participants was under drug treatments other than a neurologic drug. All subjects were edentulous. None of the selected control healthy participants had any cognitive symptoms or any sign or symptom of dementia. Control group health status was confirmed through an interview conducted by a final year dental student.
Exclusion criteria were as follows: having any other systemic disease, having periodontal disease, medications taken other than neurologic drugs, smoking, other dementias, and poor oral hygiene.
Some limitations of our study were as follows: Oral conditions of all patients were not the same. Oral situations such as inflammation and saliva quality and quantity can affect study results. Disease severity, which can alter study findings, was not taken into consideration. Our selected patients with AD were in the early stage of the disease. Late stage of disease can alter study results. We had some difficulties in saliva collection because some patients with AD group had xerostomia or poor cooperation.
A questionnaire about demographic data, disease duration, treatment of disease, and oral health condition was filled for all participants.
Sample size was calculated according to the results of a study conducted by Sayer et al 4 using a sample size calculation formula. On the basis of the results of Sayer et al's study, and the mean (SD) of the AChE enzyme, we arrived at a sample size of 30 for the group with AD at 99% significance level ( = 0.01) and 80% statistical power ( = 20%).
After the neurologist's confirmation, intraoral clinical examination was carried out. Oral mucosa of all patients was examined and when pathological states such as candidiasis, oral ulcer, and any oral disease existed, a trained final year dental student excluded patients.
Unstimulated, whole saliva samples were collected from 8 to 10 AM; the selected subjects were educated on mouth washing, avoiding any oral stimulation, and eating 90 min before saliva sampling. 24 Whole saliva specimens were collected in sitting and anterior head position in falcon tubes within 5-10 min. The samples were put on ice, transferred to the laboratory in less than 20 min, and stored at −80 • C until the analysis.
All saliva samples were centrifuged at 3000 rpm and saliva debris and squamous cells were separated for 10 min. AChE and PChE activities were measured by spectrophotometric assay using the Ellman colorimetric method, which was used for the salivary enzymes. In this assay, Butyrylthiocholine iodide and acetylthiocholine iodide were used as substrates for PChE and AchE, respectively. The color developed from 
RESULTS
Age range (mean ± SD) was 56-85 y (70.57 ± 6.317) in the group with AD and 57-85 y (66.50 ± 8.046) in control subjects. The number of males and females was equal (50%) in each group (Table 1) .
Salivary AChE and PChE activities were significantly increased in patients in the AD group, in comparison to the control group. Although enzymatic activity was higher in males, the difference between males and females was not significant (Table 2 ). There was also negative correlation between age and enzyme activity. However, this decrease was not statistically significant. The results showed no statistically significant correlation between disease duration and enzyme activity but in patients with longer disease history the enzyme activity was lower (Table 3 ). In addition, enzyme distribution index was normal in both patients and control groups. Pearson correlation coefficient between AChE and PChE was 0.280, which showed statistically significant correlation between the two enzymes (P value = 0.033).
DISCUSSION
Life expectancy and subsequently the number of old people are increasing worldwide. Therefore, a medical problem such as AD as the main cause of dementia is growing among the elderly. 28 Although early diagnosis is an important primary goal in AD, unfortunately, the central nervous system marker detection that has been carried out using CSF samples is invasive, specialized, dangerous, and unpleasant with the stress response. 4, 29 Simple and noninvasive techniques such as saliva biomarker assay for clinical diagnosis of AD are very useful, because AD diagnosis is very complicated. 28, 30 The measurement of salivary AChE activity causes people minimal discomfort. 4 Salivary AChE and PChE can be used for early detection and disease monitoring in elderly persons with AD.
This study showed higher activities of these enzymes in AD patients compared to the control group. Contrary to our results, other studies showed that AChE level decreased in serum and CSF. 31, 32 Meanwhile, some studies have reported no changes. 33, 34 Bakhtiari et al 13 also showed no differences in salivary AChE activity based on gender, age, and disease duration in patients with AD.
These different results might be due to the type of sample, sampling methods, drug treatment, and nonlinear changes of enzyme with regard to disease progression.
AChE was related to dental caries, 35 and results obtained from saliva samples might not be comparable to that obtained from other samples such as serum and CSF.
One study showed that patients with AD had bad oral health in comparison to a healthy age-matched group. Patients with AD had more caries, periodontal disease, candidiasis, and salivary quantity and quality changes. 36 In our study, we did not evaluate mucosal lesions, and all patients were edentulous.
In this study, it was seen that salivary PChE activity was increased in patients with AD compared to the control group. Ryhaneh's result showed no relation of PChE activities in saliva and serum samples. 25 Therefore, the level of enzymes in saliva may be influenced by many local factors and does not show serum level in this disease. It is recommended to evaluate salivary and serum level and the association of enzymes with drug treatments in another study and compare the results.
In another study, when teeth were not cleaned for 1 wk, salivary PChE activities increased significantly. ChE activity in the mouth may be due to bacteria and food particles. 25 Salivary PChE has multiple origins such as salivary glands, micro-organisms, leukocytes, and gingival cervicular fluids. 25, 26 Salivary PChE activity increased because of poor oral hygiene in the gingival cervicular fluid of patients with rapidly progressive juvenile periodontitis. 37 Periodontal therapy reduced the mean PChE activity in whole saliva. 26 In this study, we examined whole saliva but gingival cervicular fluid in each salivary gland and pathological condition of oral cavity and gingival cervicular fluid may change these results. In our study, all patients were aged 50 years or more, wore dentures, and were edentulous. We excluded patients with periodontal disease, gingival inflammation, and oral soft tissue lesions. Other studies have shown that caries and the oral condition influence AChE and PChE levels in saliva. 4, 25 According to our results, there was a linear correlation between age and enzyme activities. There is also a report showing a decrease in the enzyme levels with age. 13 In the present study, we did not evaluate the relationship between salivary volume and enzymatic activity, but it might be useful to assess the relationship between flow rate, the volume of saliva, and enzyme level in younger adults compared to the elderly because low saliva production is common among the elderly. 30 Salivary volume or protein content variations can be corrected by using the ratio of enzyme activity to protein level (a.u./mg protein), rather than sample volume. In this study, we also evaluated ACh activity relative to total saliva protein, and the same result was obtained.
Patients taking drugs with salivary adverse effects and patients who were under drug treatment were also were excluded from our study.
We collected all saliva samples at the same time for all participants to eliminate diurnal effect on enzyme level.
In AD up to 90%, decrease in AChE activity has been observed, and low brain cholinergic activity is the main finding in AD. 13 AChE shows cholinergic activity. The destruction of cholinergic neurons in the early stages of AD leads to significant acetylcholine reduction, which is a key finding in AD. CSF samples are used for biomarker detection in AD. However, obtaining CSF is a very invasive, specialized, and painful procedure. 4 AChE is secreted in the central nervous system, peripheral nervous system, muscles, blood cells, and saliva. Saliva sample as a body fluid can be collected in an easy and comfortable manner. 4, 38 Farah et al 21 concluded that salivary AChE could not be used as a diagnostic marker. This enzyme can be considered only for disease pathophysiology and parasympathetic activity monitoring. They suggested more studies in different disease stages, treatment programs for patients, and suitable saliva sample collection and sample storage environment for evaluation of diagnostic probability of AChE in patients with AD.
Studies on AChE levels in saliva and AD have shown contradictory results. 4, 10, 13, [30] [31] [32] [33] Our study was performed in the early stage of AD and showed increased levels of salivary AChE and PChE. Regarding few studies done on this topic in different situations, it is difficult to definitively conclude that salivary AChE and PChE are biomarkers for AD disease diagnosis, progression, and differentiation from other types of dementia.
Our study limitations were as follows:
1. The enzymatic activity between saliva and serum was not compared. Enzymatic activity may be different in saliva and serum and saliva may not be able to show serum changes.
2.
All study groups did not receive therapy. Drug therapy for AD can affect salivary enzymes.
3.
There was a probability that unobserved and possibly unknown confounders might influence our results.
4.
One investigator obtained saliva samples of two groups but laboratory studies were performed blindly.
5.
Although we tried to exclude patients with diabetes and other overt systemic disease, AChE might be altered in any other disease and that could act as a confounding factor.
Therefore, we suggest that more studies be performed to consider these factors.
A diagnostic study is needed with a different design and methodology to confirm the possibility of using salivary AChE and PChE as biomarkers for AD diagnosis.
CONCLUSION
Since AChE and PChE were increased in saliva samples of patients with AD, it can be concluded that there was an association between enzyme changes and AD. Salivary AChE and PChE might be considered biomarkers of AD for disease diagnosis, progression, and differentiation from other types of disease.
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